Pharmaceutical company, Shield Therapeutics (LON: STX ), has announced the appointment of Dr. Christian Schweiger as a Non-Executive Director with immediate effect.
Dr. Schweiger co-founded Shield in 2008 and was more recently employed by the company between March 2016 and April 2017 in a senior medical science capacity.
As a senior medical affairs and clinical development executive, the group said Dr. Schweiger has ‘substantial experience working with both large and small pharmaceutical companies.’
Shares in Shield Therapeutics closed at 91.5p on Thursday afternoon.
Dr Schweiger is also Lecturing Professor in Pharmaceutical Medicine at the University of Essen and ‘actively working’ with different international patient and professional associations.
"I am delighted that Christian has agreed to join the board of Shield bringing his previous knowledge of the Company and Feraccru, and also his extensive experience in medical affairs and clinical development,” said Hans Peter Hasler, Chairman of Shield Therapeutics.
Schweiger currently owns 4,114,300 ordinary shares of 1.5p each in STX representing 3.5% of the Company's issued share capital, and therefore is not considered to be independent.
Follow News & Updates from Shield Therapeutics here: